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Abstract
Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-
augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships
with 0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit).
Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were
analyzed further to determine appropriate cutpoints of relative A1C benefit.
Results: Baseline A1C 9.1%, age at randomization 36 years, and age at diabetes diagnosis of 17 years were
associated with a greater SAP benefit relative to MDI than other cutpoints.
Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at
randomization experienced the most benefit from SAP therapy.
Introduction
Among adult subjects in the Sensor-Augmented PumpTherapy for A1C Reduction (STAR) 3 study,1,2 which
compared sensor-augmented pump (SAP) to multiple daily
injection (MDI) therapy for 1 year, SAP therapy resulted in a
greater 1-year absolute change in A1C compared with con-
tinued MDI therapy.1 (Participating centers are listed in the
Appendix.) Initiating SAP therapy is expensive and requires a
substantial time commitment on the part of both patient and
provider. Therefore, it may be useful to identify baseline
factors in adults that are associated with an enhanced or di-
minished benefit of SAP relative to continuing MDI.
Presentations that reported portions of this research have
been published in abstract form.3,4
Subjects and Methods
Study conduct
Study eligibility criteria included type 1 diabetes, 7–70
years of age, use of MDI with a long-acting insulin analog in
the previous 3 months, A1C between 7.4 and 9.5%, and two or
fewer severe hypoglycemic events (defined as ones absolutely
requiring assistance from another person and preferably ac-
companied by a confirmatory blood glucose measurement of
<50 mg/dL) in the previous year. Subjects were randomized
to SAP therapy (MiniMed Paradigm REAL-Time System,
Medtronic Inc., Northridge, CA) with insulin aspart or MDI
using insulin aspart and insulin glargine. Clinicians and
subjects optimized therapy on an individual basis, and A1C
was obtained at quarterly visits. Training and visit schedules
were similar between groups. All subjects completed 1 week
of continuous glucose monitoring (CGM) at baseline, 6
months, and 1 year to collect glycemic outcomes from both
study groups.1,2 Baseline and in-study characteristics of pe-
diatric subjects as predictors of A1C benefit will be presented
elsewhere.
Statistical methods
Baseline characteristics were analyzed to determine if
they predicted 0.5% A1C reduction without severe
1Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
2Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California.
3Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon.
4International Diabetes Center at Park Nicollet, Minneapolis, Minnesota.
5Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, North Carolina.
6Diabetes Business Unit, Medtronic, Inc., Northridge, California.
7Division of Endocrinology, Brody School of Medicine at East Carolina University, Greenville, North Carolina.
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hypoglycemia at 1 year using a univariate logistic regression
model and a multivariate logistic regression model that used a
backward elimination procedure to keep variables with
P< 0.05. Receiver operating characteristic (ROC) curves de-
termined whether key baseline characteristics predicted a
0.5% reduction in A1C without severe hypoglycemia at 1
year and were adjusted for baseline A1C and mean sensor
glucose value. C-scores (equivalent to areas under the curve)
of different categories were compared using a nonparametric
test. Treatment differences for subjects with certain baseline
characteristics were derived from an analysis of covariance
model that included categorical variables (treatment group
and age at randomization, age at diagnosis, or baseline A1C)
and continuous variables (mean glucose and baseline A1C) as
fixed effects.
Analyses were performed using SAS version 9.2 (SAS In-
stitute, Cary, NC). All P values are two-sided.
Results
Subjects
There were 495 subjects randomized in STAR 3, including
336 adults (169 to SAP, 167 to MDI). Seven adults did not have
a follow-up A1C. Of the resulting intention-to-treat analysis
population of 329 adults, 24 withdrew from the study before
completing the 1-year follow-up. Adults were similar be-
tween groups at baseline in all characteristics except mean
weight and student status, which were significantly higher
among MDI subjects (reported by Bergenstal et al.1).
Baseline predictors of A1C reduction
Baseline A1C in both study groups, age at randomization,
and age at diagnosis of diabetes in the SAP group and mean
sensor glucose value in the MDI group predicted 0.5% A1C
reduction without severe hypoglycemia (all P< 0.05; Table 1).
In a comparison of baseline characteristic values to mean
1-year A1C and mean A1C change (Table 2), higher baseline
A1C predicted higher end point A1C and greater A1C re-
duction with SAP than MDI. Younger age at randomization
(35 years) and diagnosis (16 years) was associated with
slightly higher 1-year A1C and less differential change in A1C
with SAP compared with MDI.
ROC curves (Fig. 1) showed that A1C 9.1%, age at ran-
domization of 36 years, and age at diagnosis of 17 years
were associated with higher C-scores. C-scores for categories
of these characteristics were significantly different from one
another (all P< 0.01). Similar results were found in an analysis
of the treatment difference between SAP and MDI within
baseline characteristic categories (Table 3).
Conclusions
We are not aware of a device trial in which A1C lowering
versus an active comparator was as great in type 1 diabetes
as SAP therapy in STAR 3,1 but the necessary time and re-
source investment to initiate SAP therapy is high. We used
statistical models to determine whether certain baseline
characteristics were predictive of 1-year A1C benefit. We
then used cutpoint comparisons with ROC curves to deter-
mine the relative benefit of SAP to MDI for subjects in dif-
ferent baseline categories. Higher baseline A1C in both study
groups and older age at randomization and diagnosis in the
SAP group were associated with greater benefit. Baseline
CGM-derived values did not predict response to SAP or
continued MDI therapy.
Although higher baseline A1C predicted a higher 1-year
A1C in both study groups, the reduction in A1C at higher
baseline values was greater for SAP than MDI. Specifically,
the difference in 1-year A1C change for SAP subjects was 1.3%
at A1C9.1% where ongoing MDI showed very little benefit.
However, the benefit at lower A1C (8%) was robust at 0.6%.
Age at diagnosis of 16 years and age at randomization of
35 years were associated with similar benefits of SAP and
MDI, approximately 0.3% each. ROC and treatment differ-
ence by baseline characteristic analyses, similarly, demon-
strated greater 1-year A1C benefit of SAP among subjects with
baseline A1C of 9.1%, age at randomization of 36 years,
and age at diagnosis of 17 years.
These results are consistent with a recent study of CGM
versus self-monitoring of blood glucose5 and several meta-
analyses of insulin pump use versus MDI6–8 that have sug-
gested associations between A1C reduction and baseline
A1C or age, although not to the level of detail presented in
our report. CGM was associated with greater A1C benefit
among people with baseline A1C8.0% and age25 years.5
Insulin pump use was associated with greater A1C benefit
among people with baseline A1C >6.5% to 10%4 and an age
of 18 years.7 There were also statistical associations with-
out specification of direction between A1C benefit from
insulin pump use and baseline A1C and age; in that meta-
analysis, however, lower severe hypoglycemia from insulin
pump use was specifically associated with older age and
higher baseline A1C.8












A1C 0.008 0.003 0.002 0.02
Documented SMBG/day NA NA 0.96 0.68
BMI NA NA 0.80 0.39
Age at randomization 0.01 NA 0.003 0.24
Duration of diabetes NA NA 0.37 0.33
Age at diagnosis NA NA 0.048 0.86
Smoking (yes/no) NA NA 0.87 0.44
Alcohol use (yes/no) NA NA 0.69 0.58
Sex (M/F) NA NA 0.50 0.60
SD during 1-week
screening
NA NA 0.96 0.22
Mean sensor glucose
value
NA 0.01 0.88 0.10
Model 1 is a multivariate logistic regression model using
backward selection keeping those variables with P< 0.05 that detects
whether the characteristic predicts a 0.5% change in A1C without
severe hypoglycemia. Model 2 is a univariate logistic regression
model that detects whether the individual characteristic predicts a
0.5% change in A1C without severe hypoglycemia. P values
represent correlation between baseline characteristic and 1 year
0.5% change in A1C without severe hypoglycemia.
BMI, body mass index; MDI, multiple daily injection; NA, not
available (dropped from logistic backward selection procedure);
SAP, sensor-augmented pump; SMBG, self-monitoring of blood
glucose.
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Table 2. Baseline Characteristics Compared with 1-Year A1C
No. of subjects Mean 1-year A1C [% (SD)] Mean change in A1C from baseline to 1 year [% (SD)]
Baseline characteristic SAP MDI SAP MDI SAP MDI
A1C
8 % 65 60 7.1 (0.5) 7.6 (0.7) 0.7 (0.5) 0.1 (0.7)
8.1–9% 85 88 7.4 (0.7) 8.0 (0.8) 1.1 (0.8) 0.6 (0.8)
9.1% 16 15 7.7 (0.7) 9.0 (1.1) 1.6 (0.7) 0.3 (1.0)
Age at randomization
35 years 59 58 7.4 (0.7) 8.0 (1.0) 0.7 (0.8) 0.4 (0.9)
36 – 50 years 58 68 7.2 (0.7) 8.0 (0.9) 1.1 (0.7) 0.3 (0.8)
51 years 49 37 7.3 (0.6) 7.8 (0.6) 1.1 (0.7) 0.4 (0.7)
Age at diagnosis
16 years 61 70 7.3 (0.7) 7.8 (0.8) 0.8 (0.8) 0.5 (0.7)
17 – 30 years 57 49 7.3 (0.6) 8.0 (1.0) 1.0 (0.7) 0.2 (0.9)
31 years 48 44 7.3 (0.7) 7.9 (0.9) 1.1 (0.7) 0.3 (0.8)
Mean sensor glucose value
160 mg/dL 50 48 7.2 (0.6) 7.7 (0.7) 1.0 (0.7) 0.5 (0.7)
161 – 190 mg/dL 57 68 7.3 (0.7) 7.9 (0.9) 1.0 (0.7) 0.3 (0.8)
191 mg/dL 59 47 7.4 (0.7) 8.1 (0.9) 1.0 (0.8) 0.4 (0.9)
MDI, multiple daily injection; SAP, sensor-augmented pump.
FIG. 1. Receiver operator characteristic curves of baseline A1C, age at randomization, and age at diagnosis plotted against
1-year 0.5% A1C reduction without severe hypoglycemia and adjusted for baseline A1C and mean sensor glucose values.
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It is important to note that this report does not consider any
post-baseline behaviors that may impact A1C benefit, such as
the frequency of blood glucose self-monitoring or the number
of boluses administered. As previously noted among the SAP
group, increasing sensor wear was significantly associated with
larger decrements in A1C.1 Limitations of the STAR 3 study
include the fact that it was a necessarily unblinded comparison
of SAP and MDI treatments, that it was not designed to eval-
uate the incremental effects of insulin pump therapy or CGM
sensors in isolation, and that the A1C inclusion criteria (7.4–
9.5%) may limit the generalizability of its results.
This report suggests that SAP, which is effective in lower-
ing A1C in adults with type 1 diabetes inadequately con-
trolled on MDI,1 has greater A1C-lowering benefit among
adults with higher baseline A1C, older age at randomization,
and older age at diagnosis (treatment difference ranged from
0.5% to 1.3%) than other adults in the study (treatment
difference ranged from 0.4% to 0.5%).
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Appendix
STAR 3 Study Group
The following clinical centers are listed in alphabetical or-
der by city name. Primary investigators (PI), sub-primary
investigators (Sub-PI), study coordinators (CO), and diabetes
educators (DE) are listed with their affiliated centers:
 Mountain Diabetes and Endocrine Center, PLLC,
Asheville, NC: Wendy S. Lane, M.D. (PI); Kristen Arey
(CO); Terri Przestrzelski, R.N., C.D.E. (DE)
 Joslin Diabetes Center, Boston, MA: Sanjeev Mehta,
M.D. (PI); Lori Laffel, M.D., M.P.H. (PI); Jyoti Aggarwal,
M.H.S. (CO); Katherine Pratt, R.N., C.D.E. (DE)
 University of North Carolina School of Medicine, Chapel
Hill, NC: John B. Buse, M.D., Ph.D. (PI); Michelle Duclos,
M.P.H., CCRC (CO); Joseph Largay, P.A.-C., C.D.E. (DE)
 Ohio State University College of Medicine, Columbus,
OH: Kwame Osei, M.D., FACE, FACP (PI); Cecelia
Casey-Boyer, R.N., M.S., C.D.E. (CO, DE); Hollie Breed-
love, M.S., R.D., L.D. (CO, DE)
 University of Colorado Denver, Barbara Davis Center,
Denver, CO: Robert Slover II, M.D. (PI); Stephanie Kassels,
R.N., B.S.N. (CO, DE); Sally Sullivan, R.N., C.D.E. (DE)
 Duke University Medical Center, Diabetes Research
Clinic, Durham, NC: Jennifer B. Green, M.D. (PI); Jen-
nifer English-Jones, R.N., C.D.E. (CO, DE)
 DeVos Children’s Hospital, Grand Rapids, MI: Michael
A. Wood, M.D. (PI); Emily Gleason, R.N., M.S.N. (CO);
Laura Wagner, R.N. (DE), Thomas Symington, R.N.
(CO), Lora Kleis, R.N. (DE)
 East Carolina University, Diabetes and Obesity Center,
Greenville, NC: Robert J. Tanenberg, M.D., FACP (PI);
Carolyn Knuckey, L.P.N. (CO, DE); Savanna Cum-
mings, R.D., C.D.E. (DE)
 Rocky Mountain Diabetes and Osteoporosis Center,
Idaho Falls, ID: David R. Liljenquist, M.D. (PI); John E.
Liljenquist, M.D. (PI); Becky Sulik, R.D., L.D., C.D.E.
(CO, DE)
 Kingston General Hospital, Kingston, ON, Canada:
Robyn L. Houlden, M.D., FRCPC (PI); Trish LaVallee,
R.N. (CO, DE); Adrianna Breen, R.N., B.S.N. (DE); Ruth
Barrett, R.N., C.D.E. (DE)
 Scripps Institute, La Jolla, CA: George Dailey, M.D. (PI);
Athena Philis-Tsimikas, M.D. (Sub-PI); JoAnn Shartel,
R.N., C.D.E. (DE)
 Kentucky Diabetes Endocrinology Center, Lexington,
KY: Lyle Myers, M.D. (PI); Diane Ballard, R.N., B.S.N.,
C.D.E., C.P.T. (CO, DE)
 Endocrinology Diabetes Clinic, University of Wisconsin
Health, Madison, WI: Melissa Meredith, M.D. (PI);
Connie Trantow, M.S., CCRC (CO, DE)
 Diabetes Research Institute, Miami, FL: Luigi F. Mene-
ghini, M.D., M.B.A. (PI); Jane Sparrow-Bodenmiller,
R.N., C.D.E. (CO); Robert Agramonte (DE)
 Minnesota International Diabetes Center, Minneapolis,
MN: Richard M. Bergenstal, M.D. (PI); Amy B. Criego,
M.D. (Sub-PI); Sarah Borgman, B.S.N., R.N., C.D.E. (CO,
DE)
 Vanderbilt University, Nashville, TN: Michael E. May,
M.D., Ph.D., C.D.E. (PI); Stephen N. Davis, M.D., MBBS,
FRCP, FACP (PI); Connie Root, R.N., M.S.N. (CO, DE)
 Yale University, New Haven, CT: Stuart A. Weinzimer,
M.D., FAAP (PI); William Tamborlane, M.D., FAAP, FACE
(Sub-PI), Lori Carria, M.S. (CO); Jennifer Sherr, M.D. (DE)
 Children’s Hospital of Orange County, Orange, CA:
Mark Daniels, M.D. (PI); Jody S. Krantz, M.D. (PI);
Susan Clark, M.D. (Sub-PI); Debbie Warner, R.N., C.D.E.
(DE); Heather Speer, M.P.H., CCRC, CHES, C.D.E. (CO);
Joane Less, R.N., B.S.N., M.B.A. (CO)
 Children’s Hospital of Philadelphia, Philadelphia, PA:
Steve M. Willi, M.D. (PI); Tammy Calvano, M.A. (CO,
DE); Erin Garth, R.N., M.S.N. (CO, DE)
 Oregon Health and Science University, Portland, OR:
Andrew A. Ahmann, M.D. (PI); Christopher Bogan
(CO); Bethany Wollam (CO)
 Mayo Clinic, Rochester, MN: Yogish C. Kudva, M.D.
(PI); Betty Wirt, L.P.N. (DE); Arlene Morris (CO)
 University of Rochester School of Medicine and Den-
tistry, Rochester, NY: Craig Orlowski, M.D. (PI); Sue
Bates, R.N., M.S.N. (CO, DE); Barbara Johnson
 Endocrine Research Solutions, Inc, Roswell, GA: John C.
Reed III, M.D., C.D.E. (PI); Jessica Tapia (CO); Karla
Wardell (CO, DE); Stacey Newsome, C.D.E. (DE)
 Memorial University of Newfoundland, Health Science
Center, St. John’s, NL, Canada: Carol Joyce, M.D. (PI); Daisy
Gibbons, R.N. (CO); Juanita O’Leary, R.N., C.D.E. (DE)
 Washington University in St. Louis School of Medicine,
St. Louis, MO; Neil H. White, M.D., C.D.E. (PI); Melanee
Coleman, R.N. (CO, DE)
 Children’s Hospital of St. Paul, St. Paul, MN: Robert C.
McEvoy, M.D. (PI); Laura Gandrud, M.D. (PI); Cathe-
rine Girard, M.S. (CO, DE); Jayne Chatterton, M.A.,
C.N.P., C.D.E. (DE)
 Utah Diabetes Center, Salt Lake City, UT: Carol M.
Foster, M.D. (PI); Trina Brown, APRN, M.S.N. (CO, DE);
Elizabeth Nuttall (CO, DE)
 Toronto General Hospital, Toronto, ON, Canada: Bruce
A. Perkins, M.D., MPH, FRCP (PI); Andrej Orszag (CO, DE)
 Endocrine Research, Inc., Vancouver, BC, Canada: Hugh
Tildesley, M.D., FRCPC (PI); Betty Pottinger, R.N.,
C.D.E. (CO, DE)
 Mid-America Diabetes Associates, PA, Wichita, KS:
Richard A. Guthrie, M.D., FAAP, FACE (PI); Phillip
Challans, M.D. (Sub-PI); Julie Dvorak, R.N., B.S.N.,
C.D.E. (CO); Belinda Childs, ARNP, M.S.N., C.D.E., BC-
ADM, R.N. (DE)
Steering Committee
 Scott Lee, M.D. (Chair and Medical Director): Med-
tronic, Inc, Northridge, CA
 Tadej Battelino, M.D., Ph.D.: University Children’s
Hospital, Ljubljana, Slovenia
 Stephen N. Davis, M.D., MBBS, FRCP, FACP: University
of Maryland Medical Center, Baltimore, MD
 Edward S. Horton, M.D.: Joslin Diabetes Center, Boston,
MA
 Richard R. Rubin, Ph.D., C.D.E.: Johns Hopkins Uni-
versity, Baltimore, MD
 Kevin A. Schulman, M.D., M.B.A.: Duke University,
Durham, NC
 William V. Tamborlane, M.D., FAAP, FACE: Yale Uni-
versity, New Haven, CT
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